Compare NEXA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | PGEN |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2017 | 2013 |
| Metric | NEXA | PGEN |
|---|---|---|
| Price | $11.07 | $3.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $10.10 | $8.33 |
| AVG Volume (30 Days) | 473.4K | ★ 5.1M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $6.99 | $938.10 |
| Revenue Next Year | N/A | $108.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $1.11 |
| 52 Week High | $14.94 | $5.47 |
| Indicator | NEXA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 55.44 |
| Support Level | $10.72 | $3.92 |
| Resistance Level | $14.84 | $4.44 |
| Average True Range (ATR) | 0.58 | 0.29 |
| MACD | 0.14 | 0.11 |
| Stochastic Oscillator | 89.11 | 72.87 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.